A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...
Goldman Sachs analyst James Yaro raised the firm’s price target on Lazard (LAZ) to $47 from $44 but keeps a Sell rating on the shares after its Q4 ...